{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:11:14Z","timestamp":1760692274232,"version":"build-2065373602"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","award":["214844"],"award-info":[{"award-number":["214844"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ashfield MedComms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although Japanese guidelines recommend fluoroquinolones (FQs) and cephalosporins for AUC (acute uncomplicated cystitis) treatment, the emergence of FQ-resistant uropathogens and inappropriate use of antibiotics may lead to treatment failure (TF), and increased healthcare costs. There is a need to understand the epidemiology, treatment patterns, and healthcare cost implications associated with AUC in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study used the Japanese Medical Database Centre database (1 October 2015\u201330 November 2021). Female patients (\u226518\u2005years) had an AUC diagnosis in the same month as \u22651 oral antibiotic prescription claim in the outpatient setting. The population was stratified into cohorts by TF status and history of AUC recurrence prior to index (pre-index recurrence). Baseline demographics were evaluated in the 12-month pre-index period and age standardized prevalence of AUC was calculated. Treatment patterns and AUC-related costs [2022 Japanese Yen (\u00a5)], were reported for the post-index follow-up period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 71\u200a476 total patients, 62.46% were aged &amp;lt;50\u2005years. Patients had evidence of TF (n = 3742; 5.24%) and pre-index recurrence (n = 3206; 4.49%). The age standardized prevalence of AUC (2016\u20132021) decreased from 8.62% to 6.02%, with up to 3.9 million women affected each year. A high proportion of patients with TF received FQs (45.48%) and third generation cephalosporins (43.37%). The mean total AUC-related costs were \u00a514\u200a905 and pharmacy costs were \u00a51059 per patient, per index AUC episode.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Healthcare providers should consider the cost implications for patients with antibiotic TF or a history of AUC recurrence when selecting antibiotics for empiric treatment in Japan.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf178","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:33:57Z","timestamp":1760690037000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and economic evaluation of acute uncomplicated cystitis in women from Japan: a retrospective cohort study"],"prefix":"10.1093","volume":"7","author":[{"given":"Madison T","family":"Preib","sequence":"first","affiliation":[{"name":"Global Real World Evidence and Health Outcomes, GSK , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia R","family":"Emden","sequence":"additional","affiliation":[{"name":"PRECISIONheor , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi C","family":"Sacks","sequence":"additional","affiliation":[{"name":"HEORStrategies, A Division of ToxStrategies , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny S","family":"Mitrani-Gold","sequence":"additional","affiliation":[{"name":"Global Real World Evidence and Health Outcomes, GSK , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinyoung","family":"Ju","sequence":"additional","affiliation":[{"name":"Real World Data Strategy and Partnerships, GSK , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"GSK , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kawamatsu","sequence":"additional","affiliation":[{"name":"GSK , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish V","family":"Joshi","sequence":"additional","affiliation":[{"name":"Global Real World Evidence and Health Outcomes, GSK , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101704335045700_dlaf178-B1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther Adv Urol"},{"key":"2025101704335045700_dlaf178-B2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nrurol.2010.190","article-title":"The epidemiology of urinary tract infection","volume":"7","author":"Foxman","year":"2010","journal-title":"Nat Rev Urol"},{"key":"2025101704335045700_dlaf178-B3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/JU.0000000000001843","article-title":"Fear and frustration among women with recurrent urinary tract infections: findings from patient focus groups","volume":"206","author":"Scott","year":"2021","journal-title":"J Urol"},{"key":"2025101704335045700_dlaf178-B4","doi-asserted-by":"publisher","first-page":"Doc03","DOI":"10.3205\/id000072","article-title":"Recurrent uncomplicated urinary tract infections: definitions and risk factors","volume":"9","author":"Cai","year":"2021","journal-title":"GMS Infect Dis"},{"key":"2025101704335045700_dlaf178-B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025101704335045700_dlaf178-B6","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/cir102","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"author":"EMA","key":"2025101704335045700_dlaf178-B7"},{"key":"2025101704335045700_dlaf178-B8","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1038\/s41598-022-09946-8","article-title":"Antimicrobial prescription practices for outpatients with uncomplicated cystitis in Japan","volume":"12","author":"Takahashi","year":"2022","journal-title":"Sci Rep"},{"key":"2025101704335045700_dlaf178-B9","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"JAID\/JSC guidelines for clinical management of infectious disease 2015 \u2212 urinary tract infection\/male genital infection","volume":"23","author":"Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy","year":"2017","journal-title":"J Infect Chemother"},{"key":"2025101704335045700_dlaf178-B10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2021.11.008","article-title":"A global perspective on improving patient care in uncomplicated urinary tract infection: expert consensus and practical guidance","volume":"28","author":"Wagenlehner","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2025101704335045700_dlaf178-B11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jiac.2024.01.011","article-title":"Third nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2020 and 2021: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and staphylococcus saprophyticus","volume":"30","author":"Wada","year":"2024","journal-title":"J Infect Chemother"},{"key":"2025101704335045700_dlaf178-B12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/pds.5237","article-title":"Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection","volume":"30","author":"Butler","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025101704335045700_dlaf178-B13","doi-asserted-by":"publisher","first-page":"e0277713","DOI":"10.1371\/journal.pone.0277713","article-title":"Treatment patterns, healthcare resource use, and costs associated with uncomplicated urinary tract infection among female patients in the United States","volume":"17","author":"Moon","year":"2022","journal-title":"PLoS One"},{"key":"2025101704335045700_dlaf178-B14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.2449","article-title":"2839. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States","volume":"10","author":"Franklin","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025101704335045700_dlaf178-B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jiac.2020.09.001","article-title":"Epidemiology of antibiotic treatment for uncomplicated cystitis in adults in Japan","volume":"27","author":"Kusama","year":"2021","journal-title":"J Infect Chemother"},{"key":"2025101704335045700_dlaf178-B16","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. Outpatients from 2000 to 2010","volume":"56","author":"Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025101704335045700_dlaf178-B17","doi-asserted-by":"publisher","first-page":"e0223409","DOI":"10.1371\/journal.pone.0223409","article-title":"Trends and impact of antimicrobial resistance on older inpatients with urinary tract infections (UTIs): a national retrospective observational study","volume":"14","author":"Nguyen","year":"2019","journal-title":"PLoS One"},{"author":"e-Stat","key":"2025101704335045700_dlaf178-B18"},{"key":"2025101704335045700_dlaf178-B19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00345-021-03913-0","article-title":"Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019","volume":"40","author":"Zeng","year":"2022","journal-title":"World J Urol"},{"key":"2025101704335045700_dlaf178-B20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10156-013-0606-9","article-title":"Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus","volume":"19","author":"Hayami","year":"2013","journal-title":"J Infect Chemother"},{"author":"EMA","key":"2025101704335045700_dlaf178-B21"},{"author":"FDA","key":"2025101704335045700_dlaf178-B22"},{"key":"2025101704335045700_dlaf178-B23","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/antibiotics10111293","article-title":"Outcomes and future prospect of Japan's national action plan on antimicrobial resistance (2016-2020)","volume":"10","author":"Gu","year":"2021","journal-title":"Antibiotics (Basel)"},{"author":"Japan Agency for Medical Research and Development","key":"2025101704335045700_dlaf178-B24"},{"author":"Japanese Society of Chemotherapy","key":"2025101704335045700_dlaf178-B25"},{"key":"2025101704335045700_dlaf178-B26","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1086\/339812","article-title":"Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens","volume":"34","author":"Raz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2025101704335045700_dlaf178-B27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/life14010106","article-title":"Update on urinary tract infection antibiotic resistance-a retrospective study in females in conjunction with clinical data","volume":"14","author":"Mare\u0219","year":"2024","journal-title":"Life (Basel)"},{"key":"2025101704335045700_dlaf178-B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijid.2017.10.001","article-title":"Staphylococcus saprophyticus: which beta-lactam?","volume":"65","author":"Pailhori\u00e8s","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2025101704335045700_dlaf178-B29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1442-2042.2010.02500.x","article-title":"Current therapy of acute uncomplicated cystitis","volume":"17","author":"Yamamoto","year":"2010","journal-title":"Int J Urol"},{"key":"2025101704335045700_dlaf178-B30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jiac.2021.03.012","article-title":"Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: conducted by the Japanese research group for urinary tract infections (JRGU)","volume":"27","author":"Wada","year":"2021","journal-title":"J Infect Chemother"},{"author":"NCT05630833","key":"2025101704335045700_dlaf178-B31"},{"key":"2025101704335045700_dlaf178-B32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5582\/ddt.2025.01028","article-title":"Gepotidacin: the first-in-class triazaacenaphthylene antibiotic approved for the treatment of uncomplicated urinary tract infections","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov Ther"},{"key":"2025101704335045700_dlaf178-B33","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1038\/s41598-023-50008-4","article-title":"Repurposing antibiotic resistance surveillance data to support treatment of recurrent infections in a remote setting","volume":"14","author":"Cuningham","year":"2024","journal-title":"Sci Rep"},{"key":"2025101704335045700_dlaf178-B34","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41598-022-14177-y","article-title":"The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study","volume":"12","author":"Lindblom","year":"2022","journal-title":"Sci Rep"},{"key":"2025101704335045700_dlaf178-B35","doi-asserted-by":"publisher","first-page":"e1344","DOI":"10.1093\/infdis\/jiae233","article-title":"Antibiotic resistance of urinary tract infection recurrences in a large integrated US healthcare system","volume":"230","author":"Ku","year":"2024","journal-title":"J Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/5\/dlaf178\/64728983\/dlaf178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/5\/dlaf178\/64728983\/dlaf178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:34:01Z","timestamp":1760690041000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf178\/8290343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf178","relation":{},"ISSN":["2632-1823"],"issn-type":[{"type":"electronic","value":"2632-1823"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,3]]},"article-number":"dlaf178"}}